biostudies-literatureChan ANIAID NIH HHS510-519https://www.ebi.ac.uk/biostudies/studies/S-EPMC7837440biostudies-literatureUnknown10(6)<h4>Background</h4>Delayed-release dimethyl fumarate (DMF) has demonstrated robust efficacy in treating patients with relapsing-remitting multiple sclerosis. Decreases in absolute lymphocyte count (ALC) are a well-known pharmacodynamic effect of DMF treatment, but lymphocyte recovery dynamics are not well characterized after discontinuation of DMF.<h4>Methods</h4>Data sources included the Biogen DMF integrated clinical trial data set, a retrospective US chart abstraction study, and data from MSBase. We assessed rate and time course of lymphocyte reconstitution after DMF discontinuation.<h4>Results</h4>The majority of patients who developed lymphopenia while treated with DMF and subsequently discontinued treatment experienced ALC reconstitution. The median time to reach ALC ≥0.8 × 10<sup>9<Neurology. Clinical practiceLymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS.PMC7837440UM1 AI144288Gold RWright KRose JKalincik TChan ASpelman TFerraro DAlvarez EBar-Or AChen CFam SWu FFox RJButzkueven HSola PMcGuigan CLechner-Scott JHaartsen JMiller CGudesblatt MHodgkinson SSpach KfalseLymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS.<h4>Background</h4>Delayed-release dimethyl fumarate (DMF) has demonstrated robust efficacy in treating patients with relapsing-remitting multiple sclerosis. Decreases in absolute lymphocyte count (ALC) are a well-known pharmacodynamic effect of DMF treatment, but lymphocyte recovery dynamics are not well characterized after discontinuation of DMF.<h4>Methods</h4>Data sources included the Biogen DMF integrated clinical trial data set, a retrospective US chart abstraction study, and data from MSBase. We assessed rate and time course of lymphocyte reconstitution after DMF discontinuation.<h4>Results</h4>The majority of patients who developed lymphopenia while treated with DMF and subsequently discontinued treatment experienced ALC reconstitution. The median time to reach ALC ≥0.8 × 10<sup>9<2020-01-01T00:00:00Z2020 Dec2025-04-04T13:04:45.083Z2021-02-21T05:04:51ZS-EPMC78374403351094710.1212/CPJ.0000000000000800